Demographic and baseline patient characteristics according to CD56 expression
| Characteristic . | CD56-positive . | CD56-negative . | P . | ||
|---|---|---|---|---|---|
| Median (range) . | No. (%) . | Median (range) . | No. (%) . | ||
| Overall | 72 (100) | 579 (100) | |||
| PETHEMA trial | |||||
| LPA96 | 4 (6) | 75 (13) | .17 | ||
| LPA99 | 41 (57) | 289 (50) | |||
| LPA2005 | 27 (37) | 215 (37) | |||
| Age, y | 41 (5-74) | 40 (2-81) | |||
| ≤ 18 | 5 (7) | 62 (11) | .44 | ||
| 19-40 | 31 (43) | 235 (41) | |||
| 41-60 | 21 (29) | 189 (33) | |||
| > 60 | 15 (21) | 92 (17) | |||
| Sex | |||||
| Male | 33 (46) | 312 (54) | .20 | ||
| Female | 39 (54) | 267 (46) | |||
| ECOG | 1 (0-3) | 1 (0-3) | |||
| 0-1 | 48 (71) | 431 (79) | .06 | ||
| 2-3 | 20 (29) | 106 (21) | |||
| Fever | |||||
| No | 48 (69) | 356 (62) | .17 | ||
| Yes | 22 (31) | 220 (38) | |||
| WBC count, × 109/L | 3.6 (0.4-162) | 2.6 (0.2-460) | .03* | ||
| ≤ 5 | 39 (54) | 360 (62) | .19 | ||
| 5-10 | 10 (14) | 50 (9) | |||
| 10-50 | 15 (21) | 132 (23) | |||
| > 50 | 8 (11) | 37 (6) | |||
| Platelet count, × 109/L | 20 (2-155) | 23 (1-222) | |||
| ≤ 40 | 56 (78) | 444 (77) | .83 | ||
| > 40 | 16 (22) | 135 (23) | |||
| Relapse-risk group | |||||
| Low | 12 (17) | 109 (19) | .85 | ||
| Intermediate | 37 (51) | 301 (52) | |||
| High | 23 (32) | 169 (29) | |||
| Hemoglobin, g/dL | 9.5 (4.6-14.3) | 9.4 (2.4-15.9) | |||
| ≤ 10 | 47 (65) | 349 (60) | .41 | ||
| > 10 | 25 (35) | 230 (40) | |||
| Fibrinogen, mg/dL | 174 (40-622) | 159 (0-777) | |||
| ≤ 170 | 32 (49) | 301 (54) | .45 | ||
| > 170 | 33 (51) | 255 (46) | |||
| Albumin, g/dL | 3.9 (2.3-4.9) | 4.0 (1.7-6.0) | .002* | ||
| ≤ 3.5 | 19 (31) | 97 (19) | .04 | ||
| > 3.5 | 43 (69) | 406 (81) | |||
| Characteristic . | CD56-positive . | CD56-negative . | P . | ||
|---|---|---|---|---|---|
| Median (range) . | No. (%) . | Median (range) . | No. (%) . | ||
| Overall | 72 (100) | 579 (100) | |||
| PETHEMA trial | |||||
| LPA96 | 4 (6) | 75 (13) | .17 | ||
| LPA99 | 41 (57) | 289 (50) | |||
| LPA2005 | 27 (37) | 215 (37) | |||
| Age, y | 41 (5-74) | 40 (2-81) | |||
| ≤ 18 | 5 (7) | 62 (11) | .44 | ||
| 19-40 | 31 (43) | 235 (41) | |||
| 41-60 | 21 (29) | 189 (33) | |||
| > 60 | 15 (21) | 92 (17) | |||
| Sex | |||||
| Male | 33 (46) | 312 (54) | .20 | ||
| Female | 39 (54) | 267 (46) | |||
| ECOG | 1 (0-3) | 1 (0-3) | |||
| 0-1 | 48 (71) | 431 (79) | .06 | ||
| 2-3 | 20 (29) | 106 (21) | |||
| Fever | |||||
| No | 48 (69) | 356 (62) | .17 | ||
| Yes | 22 (31) | 220 (38) | |||
| WBC count, × 109/L | 3.6 (0.4-162) | 2.6 (0.2-460) | .03* | ||
| ≤ 5 | 39 (54) | 360 (62) | .19 | ||
| 5-10 | 10 (14) | 50 (9) | |||
| 10-50 | 15 (21) | 132 (23) | |||
| > 50 | 8 (11) | 37 (6) | |||
| Platelet count, × 109/L | 20 (2-155) | 23 (1-222) | |||
| ≤ 40 | 56 (78) | 444 (77) | .83 | ||
| > 40 | 16 (22) | 135 (23) | |||
| Relapse-risk group | |||||
| Low | 12 (17) | 109 (19) | .85 | ||
| Intermediate | 37 (51) | 301 (52) | |||
| High | 23 (32) | 169 (29) | |||
| Hemoglobin, g/dL | 9.5 (4.6-14.3) | 9.4 (2.4-15.9) | |||
| ≤ 10 | 47 (65) | 349 (60) | .41 | ||
| > 10 | 25 (35) | 230 (40) | |||
| Fibrinogen, mg/dL | 174 (40-622) | 159 (0-777) | |||
| ≤ 170 | 32 (49) | 301 (54) | .45 | ||
| > 170 | 33 (51) | 255 (46) | |||
| Albumin, g/dL | 3.9 (2.3-4.9) | 4.0 (1.7-6.0) | .002* | ||
| ≤ 3.5 | 19 (31) | 97 (19) | .04 | ||
| > 3.5 | 43 (69) | 406 (81) | |||
ECOG indicates Eastern Cooperative Oncology Group; PETHEMA, Programa Español para el Tratamiento de Enfermedades Hematológicas; and WBC, white blood cell.
P compares continuous variables (mean WBC 17.5 vs 13.5, P = .03; and mean albumin 3.8 vs 4.0, P = .002).